Send to printer »

GEN News Highlights : Aug 6, 2009

Eden Biodesign to Manufacture Wound Healing Compound for Omnio

Swedish company Omnio Healer selected Eden Biodesign to carry out process development and cGMP mammalian cell manufacture of its lead recombinant protein candidate, which is in development for the treatment of chronic eardrum wounds. The candidate is currently in late preclinical development and is expected to enter the clinic during late 2010.

One of Karolinska Developmentā€™s portfolio companies, Omnio Healer was established in 2006 to exploit the proinflammatory properties of the anticoagulation system for applications in wound healing and anti-infectives.